Nurix Therapeutics Announces Scientific Presentations on its BTK Program at the 61st American Society of Hematology Annual Meeting

On November 18, 2019 Nurix Therapeutics, Inc., a company developing novel therapies that control disease-causing proteins, reported an oral presentation on its wholly-owned, BTK degrader program for chronic lymphocytic leukemia will be delivered by the Company’s collaborators from the National Institutes of Health at the upcoming 61st American Society of Hematology (ASH) (Free ASH Whitepaper) meeting (ASH) (Free ASH Whitepaper) (Press release, Nurix Therapeutics, NOV 18, 2019, View Source [SID1234551423]). A poster presentation will also be presented on the BTK degradation mechanism of action. ASH (Free ASH Whitepaper) is being held on December 7-10, 2019 at the Orange County Convention Center in Orlando, Fla.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ORAL PRESENTATION DETAILS:
Title: Highly Potent BTK Degradation Induced by NRX0492 As a Therapeutic Strategy for CLL
Session: 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases I

Hematology Disease Topics & Pathways: Diseases, Leukemia, Biological, Therapies, CLL, immune cells, Lymphoid Malignancies, TKI

Presenter: Deyi Zhang, Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, NIH, Bethesda, MD

Date: Saturday, December 7, 2019
Time: 1:15 p.m. EST
Location: W414AB, Level 4

POSTER PRESENTATION DETAILS:
Title: Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies
Session: 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III

Hematology Disease Topics & Pathways: Diseases, Leukemia, Biological, Therapies, CLL, immune cells, Lymphoid Malignancies, TKI

Date: Monday, December 9, 2019
Time: 6:00 – 8:00 p.m. EST
Location: Hall B, Level 2